Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Phase 1 Active not recruiting 83 enrolled Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Immutep S.A.S. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase I trial aims to investigate a potential enhancement of IMP321 immune-activating effects by new routes of administration: direct injection of IMP321 into the tumor tissue; intra-peritoneal therapy; combination of chemotherapy and/or immunotherapy/targeted therapy with active immunotherapy

Timeline

Start: 2017-08-15
Primary completion: 2026-09-30
Completion: 2026-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	800 mg	Intravenous
Subject	IMP321	Protein / enzyme biologic	1 mg	Other
Subject	IMP321	Protein / enzyme biologic	3 mg	Other
Subject	IMP321	Protein / enzyme biologic	6 mg	Other
Subject	IMP321	Protein / enzyme biologic	12 mg	Other
Subject	IMP321	Protein / enzyme biologic	24 mg	Other
Subject	IMP321	Protein / enzyme biologic	30 mg	Other

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Summary

Timeline

Drugs

Indications